Welcome to our dedicated page for Omnicell Com SEC filings (Ticker: OMCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Omnicell, Inc. (NASDAQ: OMCL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. As a publicly traded healthcare technology company focused on intelligent medication management, Omnicell files a range of reports with the U.S. Securities and Exchange Commission that describe its financial condition, risks, governance, and material events.
Investors and researchers can use this page to review Omnicell’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss topics such as revenues from connected devices, technical services, SaaS and Expert Services, and consumables, as well as the company’s strategy to transform into a digitally enabled medication management technology company. Current reports on Form 8-K provide timely updates on matters including quarterly financial results, amendments to bylaws, and the appointment of executive officers.
For users interested in governance and corporate structure, filings detail actions like the adoption of amended and restated bylaws that refine stockholder nomination procedures, address proxy rule requirements, and clarify jurisdictional provisions. Risk factor discussions in Omnicell’s periodic reports outline considerations related to economic conditions, demand for medication management solutions, regulatory and legal obligations, cybersecurity, supply chain, and competition.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the implications of Omnicell’s 10-Ks, 10-Qs, and 8-Ks without reading every page. Real-time updates from EDGAR, combined with structured access to historical filings, allow investors to follow how OMCL’s disclosures evolve over time and to connect regulatory information with the company’s broader narrative in medication management technology.
Omnicell, Inc. reported an insider equity transaction by its Chairman, President and CEO and director, Randall Lipps. On 12/15/2025, the company withheld 1,147 shares of common stock at $43.27 per share to cover taxes due upon the vesting of restricted stock units, which is a non-open-market transaction. After this tax withholding, Mr. Lipps beneficially owned 385,501 shares of Omnicell common stock directly, plus 355,861 shares held in a trust with his wife and 8,051 shares held in trust for the benefit of his children.
Omnicell, Inc. (OMCL)226 shares of common stock were withheld to cover taxes due in connection with the vesting of restricted stock units at a price of $35.12 per share. After this tax withholding, Nutt directly owns 17,342 shares of Omnicell common stock. This is an administrative equity event tied to compensation rather than an open‑market buy or sell.
Omnicell, Inc. reported an insider share disposition by its Chairman, President and CEO, Randall A. Lipps. On 11/15/2025, Lipps disposed of 8,437 shares of Omnicell common stock at a price of $35.12 per share, coded as an "F" transaction, which indicates shares were withheld to cover taxes related to vesting restricted stock units. Following this transaction, he directly owned 386,648 shares. He also held 355,861 shares in a trust with his wife and 8,051 shares in a trust for the benefit of his children.
Omnicell, Inc. executive reports routine share withholding for taxes. The company’s EVP and Chief Operating Officer reported the disposition of 4,095 shares of Omnicell common stock on 11/15/2025 at a price of $35.12 per share, coded as an "F" transaction, which indicates shares were withheld to cover taxes due on vesting of restricted stock units.
After this tax withholding, the executive beneficially owns 87,193 shares of Omnicell common stock. This balance includes an adjustment for 359 shares purchased under Omnicell’s Employee Stock Purchase Plan on 8/15/2025, as noted in the footnotes.
Omnicell, Inc. (OMCL) reported an equity award to its Executive Vice President & Chief Financial Officer, H. Baird Radford III, on a Form 4. On 11/15/2025, he received 32,932 shares of Omnicell common stock in the form of restricted stock units granted under the company’s equity incentive plan at a stated price of $0 per share, reflecting a stock-based award rather than a cash purchase. After this grant, he beneficially owns 32,932 shares directly. The award vests over time: 25% of the shares are scheduled to vest on November 15, 2026, and the remaining 75% vest in equal quarterly installments over three years on 2/15, 5/15, 8/15, and 11/15, aligning his compensation with longer-term company performance.
Omnicell, Inc. (OMCL)
Omnicell, Inc. executive reports routine stock transactions. The EVP and Chief Legal/Administrative Officer reported two transactions in Omnicell common stock. On 11/15/2025, 2,792 shares were withheld to cover taxes due on vesting of restricted stock units at a price of $35.12 per share, leaving 107,861 shares beneficially owned. On 11/17/2025, the executive sold 3,473 shares at an exact price of $34.90 per share under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2025, resulting in 104,388 shares beneficially owned after the sale. The filing is made by one reporting person.
Omnicell reported Q3 2025 results, with total revenue of $310.6 million, up from $282.4 million a year ago. Product revenue was $177.5 million and service revenue was $133.1 million. Net income was $5.5 million, or $0.12 per diluted share, versus $8.6 million, or $0.19, last year as operating expenses rose.
For the first nine months, revenue reached $870.9 million with net income of $4.1 million. Cash from operations was $96.9 million. The company ended the quarter with $180.1 million in cash and cash equivalents. Omnicell repaid the remaining $175.0 million principal of its 0.25% convertible notes due 2025 and had $167.3 million (net) outstanding on the 1.00% notes due 2029. Deferred revenues were $245.5 million, including $178.8 million current.
Stockholders’ equity was $1.22 billion. The company repurchased common stock totaling $77.6 million year‑to‑date, and shares outstanding were 44,876,522 as of October 29, 2025.
Omnicell, Inc. furnished an update on performance, announcing third-quarter 2025 financial results and an update to full-year 2025 guidance via a press release. The company provided the details in Exhibit 99.1, referenced under Item 2.02 of the report. The information in Item 2.02 and Exhibit 99.1 is being furnished and not filed under the Exchange Act.
Dimensional Fund Advisors LP filed a Schedule 13G reporting beneficial ownership of 2,364,068 shares of Omnicell Inc. Common Stock, representing 5.1% of the class. Dimensional states these shares are owned by mutual funds, commingled funds, group trusts and separate accounts for which it serves as investment adviser or sub-adviser, and it disclaims beneficial ownership while reporting its voting and dispositive powers: 2,303,090 shares of sole voting power and 2,364,068 shares of sole dispositive power. The filing confirms the position is held in the ordinary course of business and not for the purpose of changing or influencing control.